Arbutus Biopharma Corp cash flow to debt ratio of -946.44% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Arbutus Biopharma Corp's free cash flow has increased -39.05% from $-65.03M last year to $-39.64M, signaling increasing performance

Arbutus Biopharma Corp's debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Arbutus Biopharma Corp's debt has decreased relative to shareholder equity from 0.06 last year to 0.00 today, signaling strengthened financials

Arbutus Biopharma Corp has negative EBITDA, making leverage ratio unreliable

Arbutus Biopharma Corp earns at least as much interest as it pays. Interest obligations are fully covered.

Arbutus Biopharma Corp's profit margin has increased (-107.41%) in the last year from -1.13K% to 83.95%, signaling increasing performance

Arbutus Biopharma Corp's short-term assets of $94.46M exceed its short-term liabilities of $6.01M

Arbutus Biopharma Corp's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Arbutus Biopharma Corp's return on equity of 129.32%, is higher than 15.00%, indicating good performance

Arbutus Biopharma Corp's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Arbutus Biopharma Corp had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Arbutus Biopharma Corp has negative free cash flow, indicating the company is burning cash rather than generating it

Arbutus Biopharma Corp has negative free cash flow, indicating cash burn

Arbutus Biopharma Corp's yearly earnings has increased -52.09% since last year from $-69.92M to $-33.50M, signaling increasing performance

Arbutus Biopharma Corp's yearly revenue has increased 128.21% since last year from $6.17M to $14.08M, signaling increasing performance

ROIC 56.72% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Arbutus Biopharma Corp's 3-year revenue CAGR of -28.80% is negative, indicating declining revenue over the past 3 years

Arbutus Biopharma Corp had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Arbutus Biopharma Corp had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Arbutus Biopharma Corp has insufficient data to evaluate this check.

Arbutus Biopharma Corp has an earnings yield of 17.99%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Arbutus Biopharma Corp is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Arbutus Biopharma Corp has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Arbutus Biopharma Corp is overvalued relative to its fair value price of -6.12 based on Earnings Fair Value model

Arbutus Biopharma Corp has a PEG-ratio under 1 which is considered undervalued

Arbutus Biopharma Corp has a price-to-book ratio of 3.43x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Arbutus Biopharma Corp has a price-to-sales ratio of 4.67x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue